Related to Novartis Anticipates COPD Drug Filing This Year Following Positive Pivotal Study Data

• Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy
  
• FDA OKs Novartis' Drug for Childhood Arthritis
  
• Vectura, Chinese Partners Form $65M Respiratory JV
  
• Making Vaccines from Parts
  
• VC Firm Partners with Amgen, Novartis to Form 15+ Biotech Startups
  
• Multiple Phase III Trials Confirm Benefits of Nycomed’s Oral COPD Medication
  
• EU Sanctions Novartis’ Once-Daily Inhaled Therapy for COPD
  
• Forest and Almirall Report Positive Late-Stage Data for COPD Therapy
  
• Forest and Almirall Plan to File COPD Drug by Mid-2011 Despite Surprising Phase III Data
  
• Almirall and Forest Project Mid-2011 Aclidinium Filing as Third Phase III COPD Trial Triumphs
  
• Sandoz Negotiates Expanded RoW Rights to Vectura's Asthma/COPD Drug VR315
  
• GSK, Theravance Report Mixed Bag of Data for Relovair in COPD, Asthma
  
• EC Filing for Combo COPD Therapy Planned This Year
  
• Preliminary Phase III Data Is Positive for Novartis’ COPD Drug
  
• Vectura Bags $7.5M as Novartis Starts Phase III Development of COPD Therapy
  
• Novartis’ Onbrez Breezhaler Trumps Salmeterol in Phase III COPD Trial
  
• Phase III COPD Trials Show Benefits of Pairing Novartis’ LAMA with LABA Therapy
  
• Vectura, Novartis' COPD Therapy Succeeds in Fourth Phase III Study
  
• Vectura and Sosei Receive $7.5M Each with Start of Phase III COPD Trial by Novartis
  
• Novartis and Vectura Confirm Positive Data from First Phase III Study with COPD Drug